Studies have shown that M70 retains the biological function of FGF19 in reducing serum bile acid levels, as validated in phase I clinical studies.[43] However, it does not promote the growth of cancers such as liver cancer.[44] Whether M70 can be used to competitively inhibit the FGF19 receptor in the CRC cells‐HSCs interplay for treating CRC liver metastasis remains to be explored. The gene discussed is FGF19; the disease is liver cancer.